ArticleNeurochemical research2026
Formononetin Attenuates Seizure Severity and Cognitive Deficits in PTZ-Kindled Rats with Associated Changes in Oxidative Stress and P2 X 7/IL-1β/Glutamate Signalling Markers.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a chronic neurological disorder characterised not only by recurrent seizures but also by cognitive decline, neuroinflammatory responses, and oxidative stress, implicating the ATP-gated P2 X 7 receptor and downstream inflammasome signalling in epileptogenesis. Utilising the pentylenetetrazol (PTZ)-induced kindling model in rats, this research aimed to evaluate the neuroprotective and seizure-attenuating potential of the natural isoflavone Formononetin (FMNT), with emphasis on cognitive outcomes. Chronic epilepsy was induced in Groups II to V by repeated intraperitoneal administration of PTZ (40 mg/kg), while FMNT (20 and 40 mg/kg, p.o.) and sodium valproate (300 mg/kg, p.o.) were concurrently administered to the respective treatment groups. Group I received saline and served as vehicle control. Seizure parameters were assessed using the modified Racine scale. Cognition was evaluated using the Morris Water Maze (MWM) and Novel Object Recognition Test (NORT). Oxidative stress markers, neuroinflammatory mediators, and glutamate levels were quantified biochemically. Histopathological evaluation was conducted using Nissl staining, and molecular docking explored interactions between FMNT and neuroinflammatory targets. FMNT treatment produced a significant reduction in seizure severity and frequency, prolonged seizure latency, and improvements in spatial and recognition memory deficits. Additionally, FMNT increased antioxidant defences, reduced lipid peroxidation, and markedly reduced IL-1β, P2 X 7, and glutamate levels. Histological analysis confirmed preservation of neuronal architecture, while docking studies demonstrated favourable binding of FMNT with P2 X 7, NLRP3, TLR4, and caspase-1. These findings suggest that FMNT attenuates PTZ-kindling-associated seizure severity and cognitive deficits, potentially through antioxidant effects and suppression of P2 X 7/IL-1β/glutamate-associated inflammatory signalling. Further target-specific mechanistic studies are warranted.
Indexed as
Identifiers
42658280What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.